Draft:Sigmund Silber

From Wikipedia, the free encyclopedia


Sigmund Silber, MD, PhD, is a German cardiologist and academic known for his contributions to medical research and cardiology.[1]

Early life & education[edit]

Sigmund Silber was born in 19498 in Passau, Germany. After completing his secondary education in 1968, Silber achieved the equivalent of a Bachelor of Science through the Abitur in Munich, Germany. He pursued medical education at Ludwig-Maximilians-University (LMU) in Munich from 1968 to 1974.[2] In 1986, he completed his PhD-equivalent thesis "Habilitation" on "Nitrate Tolerance: Induction, Rational Circumvention and Consequences for a Combination Therapy" at LMU.

Research & career[edit]

Concurrently, from 1970 to 1974, he was a Research Associate at the Institute of Experimental Pharmacology at the University of Munich.[3] In 1974, Silber earned his United States Medical License (ECFMG). The following year, he defended his thesis "The Effects of Aescin on Circulation" at the University of Munich, earning an MD with Magna cum Laude honors and obtained his medical license in Germany.

Between 1982 and 1986, Silber was an Assistant Professor at the Medizinische Klinik Innenstadt of Ludwig Maximilians-University, Munich. He also served as Director of Nuclear Cardiology, member of the Isotope and Formulatory Committee at the University of Munich, and Director of the ST-Segment Holter-Monitoring Laboratory at the university.

He also served as an Associate Professor in the Department of Medicine, Division of Cardiology at the University of Alabama at Birmingham (UAB), USA, from 1987 to 1989.[4] During his tenure at UAB, he held the positions of Director of the Holter-Monitoring Laboratory and Pharmacology Clinic in Birmingham, continuing his involvement in cardiology research and clinical practice.

Sigmund Silber's research has primarily concentrated on the diagnosis and treatment of coronary artery disease.[5] His involvement in various clinical multicenter studies has contributed to the broader cardiology field, especially in enhancing interventions for coronary artery conditions.[6][7]

Awards & honors[edit]

Dr. Sigmund Silber has been recognized with fellowships from several cardiology organizations, including the European Society of Cardiology (FESC), the American College of Cardiology (FACC), and the American Heart Association (FAHA).[8]

Notable publications[edit]

Throughout his career, Sigmund Silber has made significant contributions to cardiology through his research studies and publications. Below is a selection of his works as the first author in respected cardiology journals:

  • Silber, S., et al. "Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation." European Heart Journal; 35:1949-1956 (2014).[9]
  • Silber, S., et al. "Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program." JACC Cardiovascular Interventions; 6:366-377 (2013).[10]
  • Silber, S., et al. "Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the resolute all comers trial." Lancet, 377:1241-1247 (2011).[11]
  • Silber, S., et al. "Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: The EUROSTAR-II randomised clinical trial." EuroIntervention; 7:64-73 (2011).[12]
  • Silber S., et al. "Clinical results after coronary stenting with the genous bio-engineered R stent: 12-month outcomes of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry." EuroIntervention; 6:819-825 (2011).
  • Silber S., et al. "Final 5-year results of the TAXUS-II trial: A randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions." Circulation; 120:1498-1504 (2009).[13]

References[edit]

  1. ^ "Professor Sigmund Silber". esc365.escardio.org. Retrieved 2024-05-07.
  2. ^ Schneider, Harald J.; Friedrich, Nele; Klotsche, Jens; Pieper, Lars; Nauck, Matthias; John, Ulrich; Dörr, Marcus; Felix, Stephan; Lehnert, Hendrik; Pittrow, David; Silber, Sigmund; Völzke, Henry; Stalla, Günter K.; Wallaschofski, Henri; Wittchen, Hans-Ulrich (2010-04-01). "The Predictive Value of Different Measures of Obesity for Incident Cardiovascular Events and Mortality". The Journal of Clinical Endocrinology & Metabolism. 95 (4): 1777–1785. doi:10.1210/jc.2009-1584. ISSN 0021-972X. PMID 20130075.
  3. ^ Silber, Sigmund; Vogler, A. C.; Krause, K. -H.; Theisen, K. (1987-05-01). "The Haemodynamic and Anti-Ischaemic Effects of a Single Tablet of 80mg Isosorbide Dinitrate in Slow-Release Formulation and a Review of Nitrate Tolerance". Drugs. 33 (4): 69–79. doi:10.2165/00003495-198700334-00014. ISSN 1179-1950.
  4. ^ Silber, Sigmund; Vogler, Astrid C.; Krause, Karl-Heinz; Vogel, Margot; Theisen, Karl (November 1987). "Induction and circumvention of nitrate tolerance applying different dosage intervals". The American Journal of Medicine. 83 (5): 860–870. doi:10.1016/0002-9343(87)90643-7. ISSN 0002-9343. PMID 3674093.
  5. ^ "escardio.org" (PDF).
  6. ^ Silber, Sigmund (December 2006). "A New and Rapid Scoring System to Assess the Scientific Evidence from Clinical Trials". Journal of Interventional Cardiology. 19 (6): 485–492. doi:10.1111/j.1540-8183.2006.00205.x. ISSN 0896-4327. PMID 17107362.
  7. ^ Silber, Sigmund; Windecker, Stephan; Vranckx, Pascal; Serruys, Patrick W (April 2011). "Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial". The Lancet. 377 (9773): 1241–1247. doi:10.1016/s0140-6736(11)60395-4. ISSN 0140-6736. PMID 21459430.
  8. ^ Silber, Sigmund (1998-01-01). "Hemostasis success rates and local complications with collagen after femoral access for cardiac catheterization: Analysis of 6007 published patients". American Heart Journal. 135 (1): 152–156. doi:10.1016/S0002-8703(98)70356-4. ISSN 0002-8703. PMID 9453535.
  9. ^ Silber, S.; Kirtane, A. J.; Belardi, J. A.; Liu, M.; Brar, S.; Rothman, M.; Windecker, S. (2014-02-07). "Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation". European Heart Journal. 35 (29): 1949–1956. doi:10.1093/eurheartj/ehu026. ISSN 0195-668X. PMID 24510638.
  10. ^ Silber, Sigmund; Serruys, Patrick W.; Leon, Martin B.; Meredith, Ian T.; Windecker, Stephan; Neumann, Franz-Josef; Belardi, Jorge; Widimsky, Petr; Massaro, Joe; Novack, Victor; Yeung, Alan C.; Saito, Shigeru; Mauri, Laura (2013-04-01). "Clinical Outcome of Patients With and Without Diabetes Mellitus After Percutaneous Coronary Intervention With the Resolute Zotarolimus-Eluting Stent: 2-Year Results From the Prospectively Pooled Analysis of the International Global RESOLUTE Program". JACC: Cardiovascular Interventions. 6 (4): 357–368. doi:10.1016/j.jcin.2012.11.006. ISSN 1936-8798. PMID 23523454.
  11. ^ Silber, Sigmund; Windecker, Stephan; Vranckx, Pascal; Serruys, Patrick W (April 2011). "Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial". The Lancet. 377 (9773): 1241–1247. doi:10.1016/s0140-6736(11)60395-4. ISSN 0140-6736. PMID 21459430.
  12. ^ Silber, Sigmund; Gutiérrez-Chico, Juan-Luis; Behrens, Steffen; Witzenbichler, Bernhard; Wiemer, Marcus; Hoffmann, Stefan; Slagboom, Ton; Harald, Darius; Suryapranata, Harry (2011). "Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial". EuroIntervention. 7: 64–73. doi:10.4244/eijv7i1a13. PMID 21550905. Retrieved 2024-05-07.
  13. ^ Silber, Sigmund; Colombo, Antonio; Banning, Adrian P.; Hauptmann, Karl; Drzewiecki, Janusz; Grube, Eberhard; Dudek, Dariusz; Baim, Donald S. (2009-10-13). "Final 5-Year Results of the TAXUS II Trial: A Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo Coronary Artery Lesions". Circulation. 120 (15): 1498–1504. doi:10.1161/CIRCULATIONAHA.109.849877. ISSN 0009-7322. PMID 19786634.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Sigmund_Silber&oldid=1223131418"